Replies to post #100047 on Biotech Values

[DewDiligence]

I am not sure but i think the NS5A inhibitor that [Presidio] are making good progress with is not the one they bought [from XTLB] but may be a derivative of that compound.

I didn’t know that. Do you have a source for this info? T.i.a.

[DewDiligence]

XTLB is (somewhat surprisingly) still around, although the ticker has been changed to XTLBY.PK. The latest news:

http://finance.yahoo.com/news/XTL-Completes-Acquisition-of-prnews-1817895426.html?x=0&.v=1